Jun-Jun Jia1, Bin-Yi Lin1, Jiang-Juan He1, Lei Geng1, Dhruba Kadel1, Li Wang1, Dong-Dong Yu1, Tian Shen1, Zhe Yang1, Yu-Fu Ye1, Lin Zhou1, Shu-Sen Zheng1. 1. Jun-Jun Jia, Bin-Yi Lin, Jiang-Juan He, Lei Geng, Dhruba Kadel, Li Wang, Dong-Dong Yu, Tian Shen, Zhe Yang, Yu-Fu Ye, Lin Zhou, Shu-Sen Zheng, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
Abstract
AIM: To investigate the effect of the ''minimizing tacrolimus'' strategy on long-term survival of patients after liver transplantation (LT). METHODS: We conducted a retrospective study of 319 patients who received LT between January 2009 and December 2011 at the First Affiliated Hospital of Zhejiang University School of Medicine. Following elimination of ineligible patients, 235 patients were included in the study. The relationship between early tacrolimus (TAC) exposure and survival period was analyzed by Kaplan Meier curves. Adverse effects related to TAC were evaluated by the χ(2) test. Routine monitoring of blood TAC concentration (TC) was performed using the PRO-Trac(TM) II Tacrolimus Elisa Kit (Diasorin, United States). RESULTS: Of 235 subjects enrolled in the study, 124 (52.8%) experienced adverse effects due to TAC. When evaluating mean TC, the survival time of patients with a mean TC < 5 ng/mL was significantly shorter than that in the other groups (911.3 ± 131.6 d vs 1381.1 ± 66.1 d, 911.3 ± 131.6 d vs 1327.3 ± 47.8 d, 911.3 ± 131.6 d vs 1343.2 ± 83.1 d, P < 0.05), while the survival times of patients with a mean TC of 5-7, 7-10 and 10-15 ng/mL were comparable. Adverse effects due to TAC in all four groups were not significantly different. When comparing the standard deviation (SD) of TC among the groups, the survival time of patients with a SD of 2-4 was significantly longer than that in the other groups (1388.8 ± 45.4 d vs 1029.6 ± 131.3 d, 1388.8 ± 45.4 d vs 1274.9 ± 57.0 d, P < 0.05), while in patients with a SD < 2 and SD > 4, the survival time was not statistically different. Adverse effects experienced in all three groups were not statistically different. In Cox regression analysis, male patients and those with a primary diagnosis of benign disease, mean TC > 5 ng/mL and TC SD 2-4 had better outcomes. CONCLUSION: The early ''minimizing tacrolimus'' strategy with a mean TC of 5-10 ng/mL and SD of 2-4 was beneficial in terms of long-term survival after LT.
AIM: To investigate the effect of the ''minimizing tacrolimus'' strategy on long-term survival of patients after liver transplantation (LT). METHODS: We conducted a retrospective study of 319 patients who received LT between January 2009 and December 2011 at the First Affiliated Hospital of Zhejiang University School of Medicine. Following elimination of ineligible patients, 235 patients were included in the study. The relationship between early tacrolimus (TAC) exposure and survival period was analyzed by Kaplan Meier curves. Adverse effects related to TAC were evaluated by the χ(2) test. Routine monitoring of blood TAC concentration (TC) was performed using the PRO-Trac(TM) II Tacrolimus Elisa Kit (Diasorin, United States). RESULTS: Of 235 subjects enrolled in the study, 124 (52.8%) experienced adverse effects due to TAC. When evaluating mean TC, the survival time of patients with a mean TC < 5 ng/mL was significantly shorter than that in the other groups (911.3 ± 131.6 d vs 1381.1 ± 66.1 d, 911.3 ± 131.6 d vs 1327.3 ± 47.8 d, 911.3 ± 131.6 d vs 1343.2 ± 83.1 d, P < 0.05), while the survival times of patients with a mean TC of 5-7, 7-10 and 10-15 ng/mL were comparable. Adverse effects due to TAC in all four groups were not significantly different. When comparing the standard deviation (SD) of TC among the groups, the survival time of patients with a SD of 2-4 was significantly longer than that in the other groups (1388.8 ± 45.4 d vs 1029.6 ± 131.3 d, 1388.8 ± 45.4 d vs 1274.9 ± 57.0 d, P < 0.05), while in patients with a SD < 2 and SD > 4, the survival time was not statistically different. Adverse effects experienced in all three groups were not statistically different. In Cox regression analysis, male patients and those with a primary diagnosis of benign disease, mean TC > 5 ng/mL and TC SD 2-4 had better outcomes. CONCLUSION: The early ''minimizing tacrolimus'' strategy with a mean TC of 5-10 ng/mL and SD of 2-4 was beneficial in terms of long-term survival after LT.
Authors: Stacey M Pollock-Barziv; Yaron Finkelstein; Cedric Manlhiot; Anne I Dipchand; Diane Hebert; Vicky L Ng; Melinda Solomon; Brian W McCrindle; David Grant Journal: Pediatr Transplant Date: 2010-10-05
Authors: P Trunečka; O Boillot; D Seehofer; A D Pinna; L Fischer; B-G Ericzon; R I Troisi; U Baccarani; J Ortiz de Urbina; W Wall Journal: Am J Transplant Date: 2010-09-14 Impact factor: 8.086
Authors: K Boudjema; C Camus; F Saliba; Y Calmus; E Salamé; G Pageaux; C Ducerf; C Duvoux; C Mouchel; A Renault; P Compagnon; R Lorho; E Bellissant Journal: Am J Transplant Date: 2011-04-05 Impact factor: 8.086
Authors: Björn Nashan; Faouzi Saliba; Francois Durand; Rafael Barcéna; Jose Ignacio Herrero; Gilles Mentha; Peter Neuhaus; Matthew Bowles; David Patch; Angel Bernardos; Jürgen Klempnauer; René Bouw; Jane Ives; Richard Mamelok; Diane McKay; Matt Truman; Paul Marotta Journal: Liver Transpl Date: 2009-02 Impact factor: 5.799
Authors: Kerstin Herzer; Martina Sterneck; Martin-Walter Welker; Silvio Nadalin; Gabriele Kirchner; Felix Braun; Christina Malessa; Adam Herber; Johann Pratschke; Karl Heinz Weiss; Elmar Jaeckel; Frank Tacke Journal: J Clin Med Date: 2020-11-05 Impact factor: 4.241
Authors: Mikel Gastaca; Patricia Ruiz; Javier Bustamante; Lorea Martinez-Indart; Alberto Ventoso; José Ramón Fernandez; Ibone Palomares; Mikel Prieto; Milagros Testillano; Patricia Salvador; Maria Senosiain; Maria Jesus Suárez; Andres Valdivieso Journal: World J Hepatol Date: 2021-03-27
Authors: María Eugenia Cornide-Petronio; Ana Isabel Álvarez-Mercado; Mónica B Jiménez-Castro; Carmen Peralta Journal: Nutrients Date: 2020-01-21 Impact factor: 5.717
Authors: Marijn Thijssen; Frank Tacke; Leen Beller; Ward Deboutte; Kwe Claude Yinda; Frederik Nevens; Wim Laleman; Marc Van Ranst; Mahmoud Reza Pourkarim Journal: EBioMedicine Date: 2020-09-24 Impact factor: 8.143